VEA
SMMT icon

Virtus ETF Advisers’s Summit Therapeutics SMMT Stock Holding History

Virtus ETF Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,979
Closed -$71K – 748
2024
Q4 		$71K Sell
3,979
-7,411
-65% -$144K 0.03% 364
2024
Q3 		$249K Buy
11,390
+200
+2% +$2.8K 0.12% 241
2024
Q2 		$87.3K Sell
11,190
-21,625
-66% -$117K 0.04% 372
2024
Q1 		$136K Sell
32,815
-2,254
-6% -$8.96K 0.07% 338
2023
Q4 		$91.5K Sell
35,069
-15,645
-31% -$32.2K 0.06% 401
2023
Q3 		$94.8K Sell
50,714
-5,049
-9% -$9.63K 0.06% 340
2023
Q2 		$140K Sell
55,763
-53,998
-49% -$98.5K 0.08% 323
2023
Q1 		$192K Buy
109,761
+66,926
+156% +$183K 0.11% 310
2022
Q4 		$182K Buy
+42,835
New +$77.9K 0.1% 321

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Virtus ETF Advisers's SMMT Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 3,979 shares — an estimated $71K sold.

Virtus ETF Advisers first reported a position in SMMT in Q4 2022 and held it in 9 quarters. The position peaked at $249K in Q3 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,979 Summit Therapeutics shares in Q1 2025, an estimated $71K.
  • Virtus ETF Advisers first reported a position in Summit Therapeutics in Q4 2022 and held it in 9 quarters.
  • Virtus ETF Advisers's Summit Therapeutics position peaked at $249K in Q3 2024.
  • 212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.